The corporate-backed genome editing technology developer Precision BioSciences, which was spun out of Duke University, floated in the middle of its range and is now valued at more than $780m.

The Baxter and Amgen-backed genome editing technology developer floated in the middle of its range and is now valued at more than $780m.

Founding investor Mercia Technologies joined fund manager Invesco for the synthetic biology contractor’s latest round, taking its total funding past the $25m mark.

AbbVie has contributed to a round that took the gene therapy developer's total funding to $129m in approximately two years.

Kyoto University has taken part in an $8.1m series A round for Alphanavi Pharma, which is developing drugs for neuropathic pain that will partly be based on the institution's research.

Parth Desai has stood down as an investment manager at NewYork-Presbyterian Ventures to offer his healthcare business acumen to venture capital firm Flare Capital Partners.

Claris Lifesciences has exited the online clinic management platform in a cash-and-share acquisition by NetMeds.

RIT spinout HHI is looking for grant funding to commercialise a cardiovascular monitoring toilet seat intended for patients recovering from heart failure.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

DSM Venturing and Strategic Health Investment Partners extended the Stanford cartilage replacement spinout's series A round, augmenting a $16m first close featuring Johnson & Johnson and Osage University Partners.